Garivulimab
- Generic Name
- Garivulimab
- Drug Type
- Biotech
- CAS Number
- 2342597-81-1
- Unique Ingredient Identifier
- CSJ7UEQ4D9
- Background
Garivulimab is under investigation in clinical trial NCT03379259 (Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors).
Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors
- First Posted Date
- 2017-12-20
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 39
- Registration Number
- NCT03379259
- Locations
- 🇪🇸
Centro Integral Oncologico Clara Campal, Madrid, Spain
🇦🇺Nucleus Network, Melbourne, Victoria, Australia
🇦🇺Linear Clinical Research, Nedlands, Western Australia, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath